[The intestinal microflora and cholestatic liver diseases]

Area of Science:

• Hepatology
• Microbiology
• Gastroenterology

Background:

• Cholestatic liver diseases (CHD) result from impaired bile flow, leading to bile acid accumulation.
• Intestinal microflora significantly influences bile acid metabolism and immune responses during CHD development.
• CHD alters gut microbiota composition and function, creating a feedback loop affecting bile acid synthesis.

Purpose of the Study:

• To elucidate the intricate relationship between intestinal microecology and cholestatic liver diseases.
• To highlight the interconnected roles of bile acids, gut flora, and liver pathophysiology.
• To explore potential therapeutic avenues by targeting the gut-liver axis in CHD.

Main Methods:

• Review of existing literature on cholestatic liver diseases, bile acid metabolism, and gut microbiota.
• Analysis of the bidirectional interactions between host and microbial factors in CHD.
• Examination of signaling pathways involving bile acid transporters and nuclear receptors (e.g., farnesoid receptors).

Main Results:

• Bile acids are crucial signaling molecules in CHD pathogenesis.
• Gut microbiota composition and function are dynamically altered in cholestatic conditions.
• The interplay between bile acids and gut microbiota influences disease progression and immune modulation.

Conclusions:

• The gut-liver axis, encompassing bile acid-microbiota interactions, is central to cholestatic liver disease.
• Targeting intestinal microecology presents a promising strategy for managing CHD.
• Further research into this axis can lead to novel therapeutic interventions for liver health.